Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.
dQ&A presented three research abstracts at ATTD 2025, an academic and professional conference of innovation and advancement in diabetes devices.
